Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise. We analyze the surgical and medical outcomes of a cohort of patients treated for OMGCT.
Patients And Methods: Data concerning diagnosis, surgery, and medical decisions were reviewed for all patients seen for postoperative management of OMGCT at the Centre Léon Bérard in Lyon and the Institut Curie in Paris between 1985 and 2003. Sixty patients aged 0.4 to 27.9 years (mean 12.8 years) at diagnosis were included.
Results: Twenty (53%) of 38 the International Federation of Gynecology and Obstetrics (FIGO) stage I tumors were staged Ix. All stage Ix tumors had been operated by a nongynecologic surgeon. Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015). The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)). There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy. Five-year overall survival was 96.7%, and event free survival was 83.3%.
Conclusion: Comprehensive staging after removal of localized OMGCT is crucial. It allows a safe observation strategy in stage Ia tumors. Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SLA.0b013e31818447cd | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Automated Literature Screening for Hepatocellular Carcinoma Treatment Through Integration of 3 Large Language Models: Methodological Study.
JMIR Med Inform
September 2025
Department of Hepatobiliary and Vascular Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis.
Objective: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines.
[Transitioning to adult oncology for adolescents and young adults (AYAs): The experience of an AYA unit].
Med Sci (Paris)
September 2025
Département de cancérologie de l'enfant et l'adolescent (DCEA), Gustave Roussy cancer campus, Villejuif, France - Équipe mobile SPIAJA, équipe spécifique de prise en charge interdisciplinaire des adolescents et jeunes adultes, Gustave Roussy cancer campus, Villejuif, France.
Supporting the transition from pediatric to adult oncology presents challenges for all stakeholders, including adolescent and young adult (AYA) patients, their parents, pediatric oncologists, and medical oncologists. In this article, we describe the different stages of this transition and the transfer of care, the obstacles to the transition, and potential solutions. We discuss the contribution of AYA care in oncology through collaborations between pediatric and medical oncologists, and the importance of multidisciplinary support for patient empowerment.
View Article and Find Full Text PDF"Colorectal Cancer Care Quality in a Developing Country: Insights from a Comparison of Teaching and Non-teaching Hospitals in Iran".
PLoS One
September 2025
Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Our study represents the first effort in the Eastern Mediterranean Region to identify disparities in the quality of colorectal cancer (CRC) care in Iran.
Methods: We established a collaborative registry program for non-metastatic CRC patients to evaluate survival rates between teaching cancer centers (TCCs) and a high-volume, non-teaching, non-cancer center (NTNC). The study included a diverse patient population and considered various factors such as cancer stage, margin involvement, adherence to guidelines for adjuvant and neoadjuvant treatments, emergency surgeries, socioeconomic status, and risk of surgery.
Short-term costs and cost-efficiency of HPV triage strategies in a high HIV-prevalence setting: Evidence from Botswana.
PLoS One
September 2025
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
Cervical cancer remains the leading cause of cancer death among women in sub-Saharan Africa and is more severe in high HIV-burdened countries due to persistent high-risk human papillomavirus (hrHPV). In 2021, the World Health Organization recommended primary hrHPV testing for cervical cancer screening; however, optimal triage strategies following positive hrHPV tests remain unclear. We conducted a prospective cost analysis of triage methods for positive hrHPV results among women living with and without HIV in Gaborone, Botswana.
View Article and Find Full Text PDFSingle-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial.
J Vis Exp
August 2025
Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University; Key Laboratory of Chongqing Health Commission for Minimally Invasive and Precise Diagnosis and Treatment of Breast Cancer;
The integration of robotic platforms in breast oncology has witnessed substantial expansion, fueled by their inherent advantages in minimally invasive access and enhanced intraoperative maneuverability. Most of the robotic-assisted breast surgery has been performed using multi-arm robots. However, the implementation of single-port robotic (SPr) systems in mammary interventions continues to undergo rigorous clinical evaluation, particularly regarding long-term oncological safety and cost-effectiveness metrics.
View Article and Find Full Text PDF